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Abstract
Background: HIV protease inhibitor (PI)-induced inflammatory response plays an important role in HIV PI-associated
dyslipidemia and cardiovascular complications. This study examined the effect of berberine, a traditional herb medicine, on
HIV PI-induced inflammatory response and further investigated the underlying cellular/molecular mechanisms in
macrophages.
Methodology and Principal Findings: Cultured mouse J774A.1 macrophages and primary mouse macrophages were used
in this study. The expression of TNF-a and IL-6 were detected by real-time RT-PCR and ELISA. Activations of ER stress and
ERK signaling pathways were determined by Western blot analysis. Immunofluorescent staining was used to determine the
intracellular localization of RNA binding protein HuR. RNA-pull down assay was used to determine the association of HuR
with endogenous TNF-a and IL-6. Berberine significantly inhibited HIV PI-induced TNF-a and IL-6 expression by modulating
ER stress signaling pathways and subsequent ERK activation, in turn preventing the accumulation of the RNA binding
protein HuR in cytosol and inhibiting the binding of HuR to the 39-UTRs of TNF-a and IL-6 in macrophages.
Conclusions and Significance: Inhibition of ER stress represents a key mechanism by which berberine prevents HIV PI-
induced inflammatory response. Our findings provide a new insight into the molecular mechanisms of berberine and show
the potential application of berberine as a complimentary therapeutic agent for HIV infection.
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Introduction
Human immunodeficiency virus (HIV) protease inhibitors (PIs)
have been used successfully in highly active anti-retroviral therapy
(HAART) for HIV infection. Incorporation of HIV PIs in
HAART causes profound and sustained suppression of viral
replication, significantly reduces the morbidity and mortality, and
prolongs the lifespan of patients with HIV infection [1]. However,
accumulating clinical evidence indicates that HAART has
changed the clinical profile of HIV infection from a sub-acute
lethal disease to a chronic ambulatory disease [2]. Dyslipidemia
specifically associated with HIV PIs has become a matter of
particular concern in the clinic [3,4]. More than 50% of patients
receiving HAART develop dyslipidemia, which is a well-known
risk factor for serious cardiovascular complications including
endothelial dysfunction and atherosclerosis [5]. Although the
mechanism underlying HIV PI-induced atherosclerosis remains to
be fully identified, an increasing body of evidence suggests that
multiple mechanisms may be involved, and individual PIs may
have different effects on lipid metabolism. The development of
other therapeutic interventions to effectively counteract the HIV
PI-associated complications is especially urgent.
Numerous pieces of evidence from both animal models and
human specimens suggest that inflammation represents one of the
major events in the pathophysiology of atherosclerosis [6]. In
addition to the accumulation of free cholesterol in macrophages,
another key characteristic of atherosclerotic lesions is the presence
of abundant inflammatory cytokines [7]. We have previously
demonstrated that HIV PIs induce the accumulation of intracel-
lular free cholesterol, deplete the endoplasmic reticulum (ER)
calcium (Ca2+) stores, induce the ER stress and subsequent
activation of the unfolded protein response (UPR), and promote
foam cell formation in macrophages [8]. Our most recent studies
have shown that HIV PIs promote the inflammatory response by
regulating RNA binding protein HuR via the ERK signaling
pathway in macrophages [9,10]. Other investigators have
suggested that HIV PI-induced ER stress response represents an
important cell signaling mechanism underlying HIV PI-induced
metabolic syndromes [11]. These observations indicate that,
similar to lipid-lowering drugs, anti-inflammatory agents and
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ER-stress modulators may be useful for the treatment of HIV PI-
induced cardiovascular complications and metabolic syndromes.
Berberine, an isoquinoline alkaloid isolated from many
medicinal herbs, such as the Chinese herb Huanglian, berberis
aquifolium, and berberis vulgaris, has been employed in traditional
Chinese medicine to treat various infectious disorders for more
than 3,000 years [12]. During the last few decades, many studies
have shown that berberine has various beneficial effects on the
cardiovascular system and significant anti-inflammatory activities
[13]. It also has been identified as a novel cholesterol-lowering
drug through a unique mechanism distinct from the current statin
therapy [14]. Furthermore, the most recent study demonstrated
that berberine suppresses the pro-inflammatory response and
improves obesity-induced lipid dysregulation by modulating AMP-
dependent protein kinase (AMPK) activity [15,16].
An increasing amount of attention has been paid to the use of
complementary and alternative medicine as a part of the treatment
for HIV infection and the complications associated with HAART
[17]. However, the scientific evidence for the use of alternative
medicines is still lacking and the molecular targets of these
beneficial effects of natural products have not been revealed. In
the present study, we examined the potential protective effect of
berberine on HIV PI-induced inflammatory response in macro-
phages. The results presented herein indicate that inhibition of ER
stress represents a key mechanism by which berberine prevents
HIV PI-induced inflammatory response. Our findings provide a
new insight into the molecular mechanisms of berberine and show
the potential application of berberine as a complimentary
therapeutic agent for HIV infection.
Results
Effect of Berberine on HIV PI-Induced TNF-a and IL-6
Expression in Macrophages
Accumulation of inflammatory cytokines is a major character-
istic of atherosclerotic lesions. It has been well-demonstrated that
TNF-a and IL-6 are mostly secreted by macrophages [7]. Our
previous studies demonstrated that HIV PIs, atazanavir, lopinavir
and ritonavir markedly increased TNF-a and IL-6 expression in
macrophages, but amprenavir had no effect [9]. Numerous studies
have reported that berberine has anti-inflammatory effects both in
vitro and in vivo [13] and the most recent studies also have shown
that berberine effectively inhibited lipopolysaccharide (LPS)-
induced TNF-a and IL-6 expression [16]. First, we examined
whether berberine is able to inhibit HIV PI-induced TNF-a and
IL-6 expression in macrophages. Mouse J774A.1 cells were pre-
treated with berberine (0.1 or 1.0 mg/ml) for 2 h, and then treated
with vehicle control or individual HIV PIs (lopinavir, ritonavir,
and atazanavir) at a clinically relevant concentration of 15 mM for
24 h. TNF-a and IL-6 protein levels in the medium were
determined by ELISA as described previously [9]. As shown in
Figure 1A and 1B, berberine significantly inhibited HIV PI-
induced TNF-a and IL-6 expression at a concentration as low as
0.1 mg/ml. Berberine also reduced the basal expression levels of
IL-6 and TNF-a at concentrations of 0.1 mg/ml and 1.0 mg/ml
respectively.
Effect of Berberine on HIV PI-Induced UPR Activation in
Macrophages
It has become increasingly evident that activation of the UPR is
closely linked to the development and progression of atheroscle-
rotic lesions. Although the mechanisms by which ER stress
inducers promote pro-atherogenic changes remain to be fully
identified, it has been demonstrated that ER stress can induce the
activation of inflammatory pathways [18]. We have previously
shown that HIV PIs activate the UPR both in macrophages and
hepatocytes [8,19]. Our recent study also indicates that UPR
activation contributes to the HIV PI-induced inflammatory
response [10]. We further examined whether berberine has an
inhibitory effect on HIV PI-induced UPR activation in macro-
phages. Mouse J774A.1 cells were pretreated with berberine for
2 h, and then treated with individual HIV PI for 4 h. As shown in
Figure 2, berberine dose-dependently inhibited HIV PI-induced
CHOP, XBP-1 and ATF-4 expression.
We further confirmed the effect of berberine on HIV PI-induced
TNF-a and IL-6 expression and UPR activation using primary
mouse macrophages. As shown in Fig. 3, treatment the mouse
peritoneal macrophages with lopinavir/ritonavir (4:1), the most
commonly usedHIV PIs in the clinic, not only significantly increased
TNF-a and IL-6 expression, but also induced the UPR activation.
Similar to the observation in cultured mouse macrophages,
berberine prevented HIV PI-induced inflammatory cytokine
expression and ER stress response in primary mouse macrophages.
Figure 1. Effect of berberine on HIV PI-induced TNF-a and IL-6
expression in J774A.1 macrophages. Mouse J774A.1 cells were
pretreated with berberine (BBR, 0.1 or 1.0 mg/ml) for 2 h, then treated
with DMSO, atazanavir (ATZV, 15 mM), lopinavir (LOPV, 15 mM), or
ritonavir (RITV, 15 mM) for 24 h. At the end of treatment, cell culture
medium was collected. The protein levels of TNF-a and IL-6 were
determined by ELISA as described in ‘‘Methods’’. Values aremean6 SD of
3 independent experiments. *p, 0.05, statistical significance relative to
vehicle control, DMSO. #p,0.05, statistical significance of the same HIV PI
treatment between control group and BBR group. A. TNF-a; B. IL-6.
doi:10.1371/journal.pone.0009069.g001
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Effect of Berberine on HIV PI-Induced ERK Activation in
Macrophages
The mitogen-activated protein kinase (MAPK) signaling
pathways are involved in regulating the expression of many
inflammatory genes [20]. It has been shown that accumulation of
free cholesterol in macrophages induces ER stress and increases
TNF-a and IL-6 expression by activating JNK, p38, and ERK
signaling pathways [7]. Our recent studies found that ERK, but
not p38 and JNK, is the key signaling pathway involved in HIV
PI-induced inflammatory response, and HIV PI-induced UPR
activation is responsible for ERK activation in macrophages [10].
It has been reported that berberine up-regulates the expression of
hepatic low-density lipoprotein receptor by activating the ERK
signaling pathway in HepG2 cells [21]. Berberine also inhibits 12-
O-Tetradecanoylphorbol-13-acetate (TPA)-induced IL-6 expres-
sion in normal human keratinocytes by preventing ERK activation
[22]. These studies suggest that berberine has a different effect on
the ERK signaling pathway in different cell types. In order to
delineate the potential signaling pathways underlying the inhib-
itory effect of berberine on HIV PI-induced TNF-a and IL-6
expression in macrophages, we further examined whether
inhibition of HIV PI-induced UPR activation by berberine is
correlated to its effect on HIV PI-induced ERK activation. As
shown in Figure 4A, in the presence of berberine, HIV PI-induced
ERK activation was completely inhibited. The p-ERK level in the
cells treated with HIV PIs and berberine is even lower than control
or berberine-treated cells. This suggests that HIV PIs may increase
Figure 2. Effect of berberine on HIV PI-induced UPR activation
in J774A.1 macrophages. Representative immunoblots from three
independent experiments for CHOP, ATF-4, XBP-1 and lamin B from
nuclear extracts of mouse J774A.1 cells pre-treated with various
amounts of berberine (BBR, 0, 0.5, 1, 2.0 mg/ml) for 2 h, then treated
with (A) atazanavir (ATZV, 15 mM); (B) lopinavir (LOPV, 15 mM) for 4 h.
Lamin B was used as loading control.
doi:10.1371/journal.pone.0009069.g002
Figure 3. Effect of berberine on HIV PI-induced TNF-a and IL-6
expression and UPR activation in primary mouse macrophag-
es. Primary mouse macrophages were pretreated with berberine (BBR,
2.0 mg/ml) for 2 h, then treated with lopinavir/ritonavir (LOPV/
RITV = 4:1, 15 mM) for 24 h. At the end of treatment, cell culture
medium was collected. (A). The protein levels of TNF-a and IL-6 were
determined by ELISA as described in ‘‘Methods’’. Values are mean 6 SD
of 3 independent experiments. *p,0.05, statistical significance relative
to vehicle control, DMSO. #p,0.05, statistical significance between
LOPV/RITV and LOPV/RITV+BBR group. (B). Representative immunoblots
for CHOP, ATF-4, XBP-1 and lamin B from nuclear extracts of primary
mouse macrophages pre-treated with various amounts of berberine
(BBR, 2.0 mg/ml) for 2 h, then treated with lopinavir/ritonavir (LOPV/
RITV = 4:1, 15 mM) for 24 h. Lamin B was used as loading control.
doi:10.1371/journal.pone.0009069.g003
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the uptake of berberine in macrophages. We further examined the
effect of HIV PIs on berberine uptake in macrophages. As shown
in Figure 4B, berberine was rapidly taken up by macrophages.
The profile of the dose-dependent uptake of berberine at 1 h is
similar to that of 24 h (Figure 4C). Although berberine had no
effect on uptake of HIV PIs (data not shown), in the presence of
lopinavir, the uptake of berberine was significantly increased
(Figure 4D). These results suggest that berberine prevents HIV PI-
induced inflammatory response by attenuating ER stress with
subsequent inhibition of ERK activation in macrophages.
Effect of Berberine on mRNA Stabilities of TNF-a and IL-6
in Lopinavir-Treated Macrophages
Posttranscriptional regulation is a major control point for the
expression of inflammatory cytokines. Our previous studies have
shown that HIV PIs induce TNF-a and IL-6 expression by
increasing mRNA stabilities [9]. In order to determine if berberine
inhibits HIV PI-induced TNF-a and IL-6 expression by regulating
the mRNA stabilities, we examined the effect of berberine on
lopinavir-induced mRNA stabilization of TNF-a and IL-6. As
shown in Figure 5, berberine completely blocked lopinavir-
induced increase of TNF-a and IL-6 mRNA stability.
Effect of Berberine on HIV PI-Induced Cytosolic
Translocation of HuR and Its Binding to the mRNAs of
TNF-a and IL-6 in Macrophages
We have demonstrated that HIV PI-induced stabilization of
TNF-a and IL-6 mRNAs is mediated through regulating the
translocation of RNA binding protein HuR from nucleus to
cytosol and the binding of HuR to the 39UTR of TNF-a and IL-
6 mRNAs [9]. HIV PI-induced HuR cytosolic translocation is
inhibited by both the MEK1 inhibitor PD98059 or over-
expression of dominant negative MEK1 mutant [10]. Since
berberine is a strong inhibitor of ERK activation in macrophages,
we speculated that berberine should have a similar effect on HuR
to the MEK1 inhibitor. We further examined the effect of
berberine on HIV PI-induced cytosolic translocation of HuR. As
shown in Figure 6A–C, berberine inhibited atazanavir and
lopinavir-induced accumulation of cytosolic HuR, but had little
effect on total cellular HuR levels. Immunofluorescence staining
further verified our initial observation. As shown in Figure 6D,
both atazanavir and lopinavir significantly increased HuR
accumulation in cytosol, but in the presence of berberine, HuR
was mainly translocated into the nucleus. As shown in online
supplement Figure S1, berberine dose-dependently induced
accumulation of HuR in the nucleus.
We further examined if berberine also affected HIV PI-induced
binding of HuR to TNF-a and IL-6 mRNAs by immunoprecip-
itating the endogenous HuR-mRNA complexes in macrophages as
described previously [9]. As shown in Figure 7, lopinavir-induced
increase of HuR binding to TNF-a and IL-6 mRNAs was
completely blocked by berberine.
Discussion
Drug-induced adverse effects not only cause significant health
problems, but also become the most frequent single cause for
termination of drug development and withdrawal of approved
drugs from the market. Accumulating clinical evidence indicates
that current anti-HIV therapy has changed the clinical profile of
HIV infection from a sub-acute lethal disease to a chronic
ambulatory disease [3,23]. The development of other therapeutic
interventions to counteract the HIV PI-induced cardiovascular
complications is especially urgent.
Figure 4. A. Effect of berberine onHIVPI-inducedERK activation in
macrophages. Representative immunoblots from three independent
experiments for phospho(p)-ERK and total (T)-ERK from the total cell lysates
of mouse J774A.1 cells treated with berberine (BBR, 0.5 mg/ml) and
individual HIV PIs (15 mM) for 4 h. ATZV: atazanavir; LOPV: lopinavir; RITV:
ritonavir.B: Time course of berberine uptake.Mouse J774A.1 cells were
treated with berberine (BBR, 5 mM) for various time periods (0 to 24 h), the
concentration of BBR in culture medium and total intracellular amount were
determined by HPLC as described in ‘‘Methods’’. C: Dose-dependence of
berberine uptake in macrophages. Cells were treated with various
amounts of berberine (BBR, 0.5 to 15 mM) for 1, 8, or 24 h. The intracellular
concentrations of BBR were determined as described above and expressed
as pmol/mg protein. D. Effect of lopinavir on berberine uptake in
macrophages. Mouse J774A.1 cells were treated with berberine (BBR,
5 mM) in the presence or absence of lopinavir (LOPV, 15 mM) for various time
periods (0 to 24 h), the concentration of BBR in culture medium and total
intracellular amount were determined by HPLC as described above.
doi:10.1371/journal.pone.0009069.g004
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In the history of drug discovery, natural products have provided
an endless source of medicine and more than 60% of approved
and pre-new drug application candidates are either natural
products or related to them [24]. Traditional Chinese medicine
(TCM) has been developed over thousands of years and has
greatly contributed to human health [25]. It is also becoming more
popular in the international society and mainly used in
combinational therapies to reduce the side effects of conventional
therapies. However, TCM mainly depends on clinical experience
and its functional mechanism is poorly understood. The scientific
evidence for the use of most of the TCM is largely lacking.
Berberine is the major component of Rhizoma coptidis
(Huanglian), a herb that has been widely used to treat infectious
diseases for more than 3,000 years [26]. During the last decade,
berberine has been extensively studied and found to have various
pharmacological activities including anti-inflammation, anti-oxi-
dation, and anti-infection [27,28]. It also has been shown that
berberine has various beneficial effects on the cardiovascular
system [29]. Furthermore, the most recent study has identified
berberine as a novel cholesterol-lowering drug through a unique
mechanism distinct from the current statin therapy [14]. In the
present study, we provide new evidence showing that berberine
prevents HIV PI-induced inflammatory response through modu-
lating ER stress signaling pathways in macrophages.
ER stress response has emerged as an important cellular
mechanism underlying various human diseases, especially for
cardiovascular disease and metabolic syndrome [30,31]. Our
previous studies indicate that activation of the UPR plays a critical
role in HIV PI-induced inflammatory response, dyslipidemia, and
cardiovascular diseases [8,9,19]. The results reported here clearly
show that berberine significantly inhibited HIV PI-induced TNF-a
and IL-6 expression and UPR activation both in cultured and
primary mouse macrophages (Figure 1–3). Recently, we further
demonstrated for the first time that HIV PI-induced expression of
inflammatory cytokines (TNF-a and IL-6) is coupled to the UPR
and ERK signaling pathways [10]. In the current study, we found
that berberine completely blocked HIV PI-induced ERK
activation (Figure 4). Although berberine has been found to be
able to regulate various signaling pathways including p-38 MAPK,
PI-3 kinase, and AMPK under various physiological/pathological
conditions, the effect of berberine on HIV PI-induced inflamma-
tory response is mainly mediated through ER stress and ERK
signaling pathways. In the CHOP knock out primary mouse
macrophages, HIV PIs fail to activate the ERK signaling pathway
[10].
The expression of inflammatory cytokines is tightly regulated
through posttranscriptional mechanisms by modulating mRNA
stability. The presence of AU-rich elements (AREs) in the 39-
untranslated region (39UTR) is essential for the rapid decay of
mRNAs of most short-lived inflammatory cytokines including
TNF-a and IL-6 [32]. There is a growing body of evidence
indicating that dysregulation of ARE-mediated mRNA decay
contributes to chronic inflammation [32]. AREs mediate their
regulatory function through association with multiple RNA
binding proteins such as HuR, AUF1 and TTP [33,34,35,36].
Our previous work demonstrated that HIV PIs increase TNF-a
and IL-6 expression by regulating the intracellular translocation of
HuR and its binding to 39UTR of TNF-a and IL-6 [9]. Our most
recent work further identified that HIV PI-induced ER stress
response is responsible for ERK activation and subsequent
increase of TNF-a and IL-6 mRNA stability and protein
expression in macrophages [10]. In this study, we demonstrated
that berberine exerts its anti-inflammatory effects through
regulating the cytosolic translocation of RNA binding protein
HuR and the binding of HuR to its target mRNAs. The
pharmacokinetic studies further demonstrated that inhibition of
HIV PI-induced ER stress and inflammatory response by
berberine is not due to the inhibition of the uptake of HIV PIs
in macrophages (Figure 4).
In summary, the current study identified a key cellular
mechanism underlying the protective effect of berberine on HIV
PI-induced inflammatory response in macrophages. Modulation of
the ER stress response represents a potential therapeutic target for
various inflammatory diseases and metabolic syndrome including
HIV PI-associated atherosclerosis. The in vivo and clinical studies
Figure 5. Effect of berberine on HIV PI-induced TNF-a and IL-
6 mRNA stability in macrophages. Mouse J774A.1 cells were
pretreated with berberine (BBR, 0.5 mg/ml) for 1 h, then treated with
lopinavir (LOPV, 15 mM) or vehicle control (DMSO) for 4 h before addition
of actinomycin D (5.0 mg/ml)(time 0). Total cellular RNA was extracted at
0, 0.5, 1, 2, and 4 h after actinomycin D addition. TNF-a (A) and IL-6 (B)
mRNA levels were determined by real-time RT-PCR as described in
‘‘Methods’’. Values are mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0009069.g005
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are needed to further determine the potential application of
berberine as a complimentary agent for HIV infection.
Materials and Methods
Ethics Statement
Mice were housed and fed standard mouse chow and tap water
ad libitum throughout the study following protocols approved by
the IACUC at Virginia Commonwealth University.
Materials
Antibodies against phospho-ERK1/2, ERK1/2, CHOP, XBP-
1, ATF-4, HuR, b-actin, lamin B, horseradish peroxidase (HRP)-
conjugated goat anti rabbit IgG, HRP-conjugated donkey anti
goat IgG and HRP-conjugated goat anti mouse IgG were from
Santa Cruz Biotechnology (Santa Cruz, CA). Berberine was
purchased from Sigma (St. Louis, MO). Amprenavir, atazanavir,
lopinavir, and ritonavir were obtained from NIH AIDS Research
& Reference Reagent Program. Recombinant mouse TNF-a and
IL6 were obtained from BioLegend (San Diego, CA). Anti-mouse
TNF-a and IL-6 antibodies, biotinylated anti-mouse TNF-a and
IL-6, and avidin-HRP were from eBioscience (San Diego, CA).
Cell Culture and Treatment
Mouse J774A.1 macrophages were cultured as previously
described [8]. HIV PIs (atazanavir, lopinavir, and ritonavir) and
Figure 7. Effect of berberine on association of endogenous
HuR with TNF-a and IL-6 in HIV PI-treated macrophages. Mouse
J774A.1 cells were pretreated with berberine (BBR, 0.5 mg/ml) for 2 h
and then treated with lopinavir (LOPV, 15 mM) for 24 h. Total cell lysates
were subjected to immunoprecipitation (IP) using either a HuR Ab or an
isotype-matched control IgG1. mRNA levels in IP materials were
detected by real-time RT-PCR using gene-specific primers as described
in ‘‘Methods’’ and expressed as fold enrichment of mRNA in HuR IP over
control IgG1 IP. Values are mean 6 SD of three independent
experiments. Statistical significance relative to vehicle control,
*p,0.05. Statistical significance of the same HIV PI treatment between
control group and BBR group, #p,0.05.
doi:10.1371/journal.pone.0009069.g007
Figure 6. Effect of berberine on HIV PI-induced cytoplasmic
translocation of RNA binding protein HuR in mouse macro-
phages. Mouse J774A.1 cells were pretreated with various amounts of
berberine (BBR, 0, 0.5, 1, 2 mg/ml) for 2 h and then treated with
atazanavir (ATZV, 15 mM) or lopinavir (LOPV, 15 mM) for 24 h. The
nuclear proteins and cytoplasmic proteins were isolated as described in
‘‘Methods’’. Three independent experiments were performed. Repre-
sentative immunoblots against HuR from (A) nuclear proteins; (B)
cytoplasmic proteins; (C) total cellular proteins. Lamin B and b-actin
were used as loading controls for nuclear proteins and cytosolic/total
cellular proteins. The density of the immunoreactive bands was
analyzed using Image J software and normalized to lamin B or b-actin
control. D. Immunofluorescent staining of cellular distribution of HuR.
Cells were pretreated with berberine (BBR, 0.5 mg/ml) for 2 h and then
treated with vehicle control DMSO, atazanavir (ATZV, 15 mM) or
lopinavir (LOPV, 15 mM) for 24 h. Expression of HuR was detected with
mouse monoclonal antibody against HuR and donkey anti-mouse IgG
conjugated with Alex Fluor-594. Nuclei were stained with DAPI. HuR
expression was visualized under a confocal fluorescence microscope
with a 406 objective using a dual filter set for DAPI and rhodamine.
Three experiments were performed that showed similar results.
doi:10.1371/journal.pone.0009069.g006
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berberine were dissolved in dimethyl sulfoxide (DMSO) and
directly added into the culture medium.
Isolation of Mouse Peritoneal Macrophages
C57BL/6 wild type (male, 6–8 weeks old, Jackson Laboratories,
Bar Harbor, ME) were injected intraperitoneally with 0.5 ml of
phosphate-buffered saline (PBS) containing 40 mg concanavalin A.
Mice were housed and fed standard mouse chow and tap water ad
libitum throughout the study following protocols approved by the
IACUC at Virginia Commonwealth University. The macrophages
were harvested 72 h after injection by peritoneal lavage. The
harvested cells were cultured in DMEM containing 10% fetal bovine
serum (FBS) and 20% L-cell-conditioned medium [8]. The medium
was replaced every 24 h until the macrophages were confluent.
Quantification of Berberine Using High Performance
Liquid Chromatography (HPLC) Assay
An Aglient 1200 Series HPLC system and a Beckman C18
reverse phase column (5 mm, 4.6 mm625 cm) were used to
quantify the berberine in cells and medium. The mobile phase was
acetonitrile: water (30:70, v/v) containing 0.08% formic acid and
0.15% ammonium acetate. The berberine was detected at a
wavelength of 346 nm. A standard curve of berberine was
constructed using weighted linear regression of peak area ratio
values of the calibration standards.
Cells were treated with 5 mM of berberine for various time
periods (0 to 14 h) or with different concentrations of berberine (0
to 15 mM) for 1, 8, and 24 h. Berberine in the cells and medium
was extracted using methanol and subjected to HPLC analysis.
The intracellular berberine was normalized with the total protein
amount of viable cells.
Western Blot Analysis
After treatment, total cell lysate, cytosolic proteins or nuclear
proteins were prepared and used for Western blot analysis as
described previously [8,10]. The density of the immunoreactive
bands was analyzed using Image J software (NIH) [8].
Enzyme-Linked Immunosorbent Assay (ELISA) of TNF-a
and IL-6
Cells were pre-treated with berberine for 2 h, and then treated
with HIV PIs or vehicle control for 24 h. At the end of the
treatment, culture media were collected and centrifuged at 14,000
x rpm for 1 min. TNF-a and IL-6 levels in the media were
determined by ELISA as described previously [9]. The total
protein concentrations of the viable cells were determined using
Bio-Rad Protein Assay reagent. Total amounts of the TNF-a and
IL-6 in media were normalized to the total protein amounts of the
viable cell pellets and expressed as ng/mg proteins.
RNA Isolation and Real-Time Quantitative RT-PCR
Total cellular RNA was isolated after treatment using the
Promega SV Total RNA Isolation System. The first cDNA was
synthesized using the High-Capacity cDNA Archive Kit. The
mRNA levels of TNF-a and IL-6 were quantified with real-time
PCR as described previously [9].
Assessment of TNF-a and IL-6 mRNA Stability
Mouse J774A.1 macrophages were pretreated with berberine
for 2 h, then treated with HIV PI (lopinavir, 15 mM) or vehicle
control for 16 h before addition of actinomycin D (5.0 mg/ml)
(time 0). Total cellular RNA was extracted 0.5, 1, 2, and 4 h after
actinomycin D addition. TNF-a and IL-6 mRNA levels were
determined by real-time RT-PCR as described in the previous
section and results are expressed as the percentage of the mRNA
amount at the time of actinomycin D addition.
Immunofluorescent Staining
Mouse J774A.1 macrophages were treated with vehicle control
(DMSO), lopinavir (15 mM) or atazanavir (15 mM) in the presence
or absence of berberine for 24 h. Cells were fixed using 3.7%
formaldehyde. The expression of HuR in the cytoplasm and
nucleus was detected by immunofluorescent staining as described
previously [9].
Immunoprecipitation of Endogenous HuR-mRNA
Complexes
To assess the effect of berberine on HIV PI-induced increase of
association of endogenous HuR with endogenous TNF-a and IL-
6 mRNAs, immunoprecipitation (IP) of endogenous HuR-mRNA
complexes was performed as described previously [9].
Statistical Methods
All data were expressed as mean 6 SD. One-way ANNOVA
was employed to analyze the differences between sets of data.
Statistics were performed using GraphPad Pro (GraphPad, San
Diego, CA). A value of p,0.05 was considered significant.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0009069.s001 (0.05 MB
PDF)
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